OUHSC Research News – Monday, May 22, 2023

Job Opening:  Associate Vice President for Research Space and Facilities

The Office of the Vice President for Research seeks applications for the position of Associate Vice President for Research Space and Facilities. The candidate must hold an academic appointment at OUHSC and be an Associate or Full Professor with a demonstrated record of leadership at the Department/College or University level. The primary job responsibilities of this position include:

• Development, implementation, and oversight of University policies and procedures related to Institutional Core Facilities and Research Space Allocation
• Provides operational oversight for University Core Facilities and Space, including Capital Improvements
• Must have 2 years background with development of blueprints and interaction with architecture and engineering groups on and off campus
• Serves on new lab and building committees related to research renovation/development and helps to interview A&E groups for specific projects

To view the complete position details, please visit https://apply.interfolio.com/125271. Deadline to submit applications is May 26, 2023.

International Ovarian Cancer Research Consortium in conjunction with the
International Society of Precision Cancer Medicine
Date: June 12 - 13, 2023 at the Omni Hotel in Oklahoma City

Description: The 2023 Meeting has been organized to provide a comprehensive overview of clinical challenges, research breakthroughs, and therapeutic innovations in two major thematic areas of cancer research, namely ovarian cancer and precision cancer medicine. This is an international conference consisting of distinguished speakers from Canada, China, India, Italy, Japan, Korea, Taiwan, Thailand, and USA with expertise in cancer biology, cancer genomics, targeted therapy, therapy resistance, personalized medicine, and cancer bioinformatics. Highly insightful papers will be presented in the form of keynote address, plenary lectures, and thematic sessions.
We will host a dinner on June 12 at the Oklahoma History Center, please RSVP at: https://ousurvey.qualtrics.com/jfe/form/SV_3n6TJfwiZzNiOFM  

Registration: https://ousurvey.qualtrics.com/jfe/form/SV_88LaN8tifTzNUN0

Contact: Emily Hulseberg  emily-hulseberg@ouhsc.edu

Spring 2023 NSF Virtual Grants Conference

Date: June 5 – 8, 2023

Description: The NSF Grants Conference is designed to give new faculty, researchers, and administrators key insights into a wide range of current issues at NSF. NSF staff will provide up-to-date information about policies and procedures, specific funding opportunities and answer attendee questions. 

Registration: https://nsfpolicyoutreach.com/

Oklahoma Center of Medical Imaging for Translational Cancer Research Centers of Biomedical Research Excellence (COBRE) Call for Proposals 2023 – 2024 Pilot Project Grants

Description: The Oklahoma Center of Medical Imaging for Translational Cancer Research invites applications for the Pilot Project Grants. The purpose of the pilot grant program is to provide seed funding to help researchers to test new research hypothesis and generate preliminary data for future extramural research grant application. The proposal should fit into the central research theme of this COBRE, which is to pursue translational biomedical research to help increase cancer detection/diagnosis accuracy or treatment efficacy by developing and/or applying novel medical imaging techniques or quantitative imaging markers. All types of studies using retrospective human subject image data, vertebrate animal models, cancer cell line models and/or the dedicated imaging phantoms are accepted.

If you have any questions regarding this COBRE pilot project program, please contact Javier Jo (javierjo@ou.edu).

Application deadline: May 27, 2023

Link to Full Announcement: Please see the attached flyer.

Please note this is NOT a solicitation for study subjects

Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:

• Alkermes Schizophrenia or Bipolar I Disorder Protocols ALKS 3831-A312 and ALKS 3831-A313
• Organon Protocol: OG-8369-301 Indication: Exocrine Pancreatic Insufficiency (EPI) This is a placebo-controlled, crossover study of adult participants with Exocrine Pancreatic Insufficiency Associated with Diabetes Mellitus without a chronic pancreatitis diagnosis.
• Organon Protocol: OG-8369-303 Indication: Exocrine Pancreatic Insufficiency (EPI) This is a comparator-controlled study of adult participants with EPI resulting from chronic pancreatitis or a partial pancreatectomy investigating a new PERT which may help reduce total pill burden for study participants.
• Janssen_Post-ACS Survey_Protocol 70033093ACS3003
• OG-6219-P001_Organon_Endometriosis_Global_13Mar23_GSID
• Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
  • Target population: adult patients with MGFA Class II to IVa gMG

Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• A multinational pharmaceutical company is seeking natural ingredients to improve sleep as alternative or add-on therapies to Melatonin.  Ingredients targeting the orexin pathway either directly or indirectly are of highest interest; ingredient must be for oral delivery in food grade (not a drug).  All sources of natural compounds are of interest.   Submission entails completion of non-confidential application. (deadline 06/05).   
• AstraZeneca is seeking applicants from final year MD and/or PhD students or Postdoctoral Researchers within three years of receiving their advanced postgraduate degree for a fully funded post-doctoral position.  Proposal in should focus on innovative technologies to improve development of novel therapeutics and treatment approaches or be an innovative idea in one of AZ’’s focus areas (cardiovascular, renal and metabolic disease, respiratory and immunology, common infectious and rare diseases).  Successful candidates will be awarded a fully funded postdoctoral position.  Submission entails completion of non-confidential application. (deadline 06/30).   

• NIH Updated Policy Guidance for Subaward/Consortium Written Agreements
  (NOT-OD-23-133)
• Notice of NIDCR Participation in PAR-23-156 Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
  (NOT-DE-23-011)
• Notice of Participation of the NICHD in NOT-MD-23-002, "Notice of Special Interest (NOSI): Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations" (NOT-HD-23-010)
• Notice of Participation of the NICHD in NOT-MD-23-003, "Notice of Special Interest (NOSI): Addressing Health Disparities Among Immigrant Populations Through Effective Interventions"
  (NOT-HD-23-011)
• NHLBI TOPMed Announces Fellowship Program to Promote Diversity, Equity, and Inclusion in the Genomic Data Science Research Workforce (NOT-HL-23-086)
• NINDS Announces Plans to Publish the NINDS Rigor Champions Prize Challenge Competition
  (NOT-NS-23-085)
• Notice of Information: Anticipated Publication of the PHS 2023-2 Omnibus Solicitations of the NIH, CDC and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications (NOT-OD-23-124)
• Notice Regarding the Data Management and Sharing Plan for Applications Submitted to PAR-22-248: HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program and PAR-22-252: Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models
  (NOT-OD-23-131)
• Notice of Participation of the NIAAA in PAR-23-191 "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)"
  (NOT-AA-23-013)
• Notice of Change to RFA-AG-24-009, "Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)" (NOT-AG-23-028)
• Notice to Extend the Expiration Date for RFA-DC-20-002 NIDCD's Mentored Research Pathway for Otolaryngology Residents and Medical Students (R25 - Clinical Trial Not Allowed)
  (NOT-DC-23-011)
• Notice of NEI Participation in RFA-OD-23-050, "Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)" (NOT-EY-23-006)
• Notice of NEI Participation in RFA-OD-23-051, "Emergency Award: RADx-UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional)" (NOT-EY-23-007)
• Notice of Correction to Due Date for Letter of Intent for RFA-MH-23-265 "Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed)" (NOT-MH-23-320)
• Notice of the Extension of the Expiration Date for NOT-OD-23-040: Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21) (NOT-OD-23-130)
• Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research (NOT-AG-23-027)
• Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (NOT-MH-23-250)

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

• Emergency Medicine Research Career Development Program in the Neurological Sciences (EMRCDP-NS) (K12 - No Independent Clinical Trial Allowed) (PAR-23-151)
  Application Receipt Date(s): August 09, 2023
• NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
  (PAR-23-183)
  Application Receipt Date(s): February 26, 2026
• Alcohol Health Services Research (R01 Clinical Trial Optional) (PAR-23-185)
  Application Receipt Date(s): July 18, 2023
• Alcohol Health Services Research (R34 Clinical Trial Optional) (PAR-23-186)
  Application Receipt Date(s): July 18, 2023
• Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) (PAR-23-187)
  Application Receipt Date(s): July 18, 2023
• Alcohol Treatment and Recovery Research (R34 Clinical Trial required) (PAR-23-188)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 18, 2023
• Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
  (PAR-23-193)
  Application Receipt Date(s): October 3, 2023, April 3, 2024, October 3, 2024, April 3, 2025, October 3, 2025, April 3, 2026
• Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) (RFA-AG-24-021)
  Application Receipt Date(s): October 23, 2023
• Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed) (RFA-AG-24-022)
  Application Receipt Date(s): October 23, 2023
• Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)
  (RFA-AG-24-023)
  Application Receipt Date(s): October 23, 2023
• Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)? (RFA-AG-24-036)
  Application Receipt Date(s): October 23, 2023
• Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)?
  (RFA-AG-24-038)
  Application Receipt Date(s): October 23, 2023
• Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed) (RFA-AI-23-029)
  Application Receipt Date(s): Multiple dates, see announcement.
• Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed)
  (RFA-AI-23-032)
  Application Receipt Date(s): August 25, 2023
• Patient Engagement Resource Centers to Inform SUD Treatment Services Research (R24 Clinical Trial Optional)
  (RFA-DA-24-016)
  Application Receipt Date(s): November 02, 2023
• Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)
  (RFA-DA-24-024)
  Application Receipt Date(s): November 02, 2023
• Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)
  (RFA-DA-24-028)
  Application Receipt Date(s): November 02, 2023
• Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required) (RFA-DA-24-029)
  Application Receipt Date(s): November 02, 2023
• Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed)
  (RFA-DK-23-009)
  Application Receipt Date(s): October 26, 2023
• Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Clinical Centers (U01 Clinical Trial Not Allowed) (RFA-DK-23-010)
  Application Receipt Date(s): October 26, 2023
• Specialized Centers for Research on Health Disparities in Uterine Leiomyoma (SCHDUL) (P50 Clinical Trial Not Allowed) (RFA-HD-24-005)
  Application Receipt Date(s): August 07, 2023
• Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) (RFA-NS-23-027)
  Application Receipt Date(s): Multiple dates, see announcement.
• Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) (RFA-NS-24-003)
  Application Receipt Date(s): July 28, 2023
• Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) (RFA-NS-24-010)
  Application Receipt Date(s): September 08, 2023

Vilcek Foundation:  2024 Vilcek Prizes for Creative Promise in Biomedical Sciences

Description:  Immigrant biomedical researchers are encouraged to apply. Applicants must have been born outside the United States and be 38 years of age or younger, but limited exceptions to the age requirement may apply to individuals who have taken caregiving, medical, military, or parental leave. Three winners will each receive a $50,000 unrestricted cash prize and be honored at a reception in New York City in April 2024. 
Complete eligibility requirements and the online application can be found at www.vilcek.org.

Application Deadline: June 12, 2023

Link to Full Announcement: https://vilcek.org/prizes/vilcek-prizes-for-creative-promise/creative-promise-prizes-biomedical-science/?utm_source=salesforce&utm_medium=email&utm_campaign=2024cpp.biomed